Welcome to our dedicated page for 22Nd Century news (Ticker: XXII), a resource for investors and traders seeking the latest updates and insights on 22Nd Century stock.
22nd Century Group Inc. develops and commercializes reduced-nicotine tobacco products built on proprietary plant biotechnology. Its VLN® combustible cigarette products use low-nicotine tobacco and are described in company materials as FDA-authorized reduced nicotine cigarettes in the United States. Company updates commonly address VLN retail distribution, state authorizations, PMTA-related product expansion, licensing strategy, tobacco-variety research and engagement with FDA and public-health stakeholders.
News also covers operating results for the tobacco business, including branded VLN products, contract manufacturing volumes, filtered cigars and other distributed tobacco products. Recent company reporting frames results around commercial expansion, cost management, higher-margin branded products and the completed exit from the hemp/cannabis business.
22nd Century Group (Nasdaq: XXII) will participate in the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on October 7, 2021. The presentation, led by CEO James A. Mish, will commence at 12:15 PM ET and can be viewed on Benzinga’s live stream channel or on the Company's Investor Relations website.
The focus will be on the Company’s advancements in plant biotechnology, particularly in tobacco, hemp/cannabis, and hops, aimed at improving health and wellness through innovative plant science.
22nd Century Group (Nasdaq: XXII), an innovative biotechnology firm focused on plant sciences, announced its participation in various virtual investor conferences in September and October 2021. Key events include a fireside chat at the BTIG Cannabis Conference on September 29, a presentation at the LD Micro Main Event on October 12, and participation in the Dawson James Small Cap Conference on October 21. CEO James A. Mish will outline business development efforts, including plans for commercialization of VLN® reduced nicotine cigarettes and proprietary hemp/cannabis initiatives.
22nd Century Group (Nasdaq: XXII) announced its entry into the global specialty hops market, marking its third plant franchise, as detailed in a shareholder update from CEO James A. Mish. The company is establishing a new subsidiary in the Netherlands to capitalize on opportunities in this market, which has an estimated $1.3 trillion total addressable market. The company aims to use its expertise in plant science and advanced breeding technologies to accelerate the commercialization of proprietary hop plants, enhancing products in the brewing and nutraceutical industries.
22nd Century Group, Inc. (Nasdaq: XXII) has appointed Anthony Johnson to its Board of Directors, enhancing its expertise in biotechnology and commercialization strategies. Johnson, a notable leader in life sciences, brings extensive experience from his roles at Kodikaz Therapeutic Solutions and Empire Genomics. His diverse background, spanning international markets, is expected to bolster 22nd Century's initiatives in tobacco harm reduction and cannabis research. This strategic move aims to drive business development and value creation as the company works on innovative plant-based technologies.
22nd Century Group (Nasdaq: XXII), a leader in plant-based biotechnology, announced CEO James A. Mish will present at the SNN Network Summer Virtual Event on August 19, 2021, at 2:30 p.m. ET. The event will be accessible via a live webcast on the company’s Investor Relations website. Attendees can request one-on-one meetings with company representatives through the conference website or by contacting investor relations directly. The company focuses on reducing tobacco harm through reduced nicotine content cigarettes and enhancing hemp/cannabis strains for better cannabinoid profiles.
On August 16, 2021, 22nd Century Group (Nasdaq: XXII) celebrated its transfer from the NYSE American to the Nasdaq Capital Market by ringing the Nasdaq Closing Bell. This move reflects the company's strategic growth in the biotechnology sector, focusing on tobacco harm reduction and hemp/cannabis research. CEO James A. Mish indicated the uplisting enhances the company's visibility and supports long-term revenue growth. The common stock will continue trading under the XXII ticker symbol.
22nd Century Group (NYSE American: XXII) announced its common stock uplisting to the Nasdaq Capital Market, effective August 16, 2021. This strategic move aims to enhance visibility to institutional investors and expand exposure to the hemp/cannabis sector as the industry progresses. CEO James A. Mish emphasized the alignment with high-achieving companies, reinforcing their commitment to reducing smoking harm through reduced nicotine tobacco products, and advancing innovations in hemp/cannabis technology.
22nd Century Group (XXII) reported record second quarter net sales of $8.4 million, up over 30% from last year. The company holds a strong cash position of $62.3 million as of June 30, 2021, enhancing its readiness for the upcoming VLN® tobacco product launch and the international expansion planned for early 2022. The FDA's review of the Modified Risk Tobacco Product (MRTP) application is progressing, with no outstanding inquiries. First revenue from its hemp/cannabis franchise is expected in Q3 2021.
22nd Century Group (NYSE American: XXII) has announced a new partnership with a leading tobacco exporter, prompting increased investment in production and testing equipment, as well as staff hiring at its North Carolina facility. The company is positioning itself for the global launch of its VLN® reduced nicotine cigarettes, anticipating FDA authorization soon. Improved testing capabilities are expected to lower production costs significantly. The firm is also seeking to expand its distribution channels.
22nd Century Group, with ticker XXII, announced a live webcast on August 5, 2021, at 10:00 AM ET to discuss its second quarter 2021 results. The company will release its results on the same day at 6:00 AM ET. CEO James A. Mish, COO Michael Zercher, and CFO John Franzino will present the results and discuss growth opportunities in the $1.3 trillion addressable market. An interactive Q&A session will follow. Interested parties can access the webcast via the company’s Investor Relations website. 22nd Century focuses on reducing tobacco harm and advancing hemp/cannabis research.